A large, long-running study following more than 355,000 adults for an average of thirteen years has found that people who drink more coffee face substantially lower risks of cirrhosis, liver cancer, and death from liver disease, with the strongest protective effect seen among those drinking five or more cups a day. The research, led by Cedars-Sinai transplant hepatologist Dr. Hyunseok Kim and published in the journal Clinical Gastroenterology and Hepatology, combined survey data, liver imaging, and blood protein analysis from the UK Biobank to build one of the most detailed pictures yet of how a habit enjoyed by billions of people worldwide appears to protect one of the body's hardest-working organs.
What the Study Found
According to reporting from ScienceDaily, Medical Xpress, and Euronews, compared with people who did not drink coffee at all, those who consumed five or more cups a day had a 32 percent lower risk of cirrhosis, a 47 percent lower risk of liver cancer, and a 42 percent lower risk of death specifically attributable to liver disease. Importantly, the researchers found a clear dose-response relationship, meaning the protective association generally strengthened as coffee intake increased, rather than appearing only above some high threshold. Benefits were detectable even among people drinking just one or two cups daily, with the effect appearing strongest in the three-to-four-cup range and continuing to build modestly beyond that.
What distinguishes this research from many previous coffee studies is the breadth of evidence supporting the association. Rather than relying solely on self-reported drinking habits and later disease diagnoses, the study incorporated liver imaging data and blood-based protein markers, allowing researchers to observe that coffee drinkers tended to have measurably healthier liver scans, with less fat accumulation, less inflammation, and less fibrotic scarring, compared with non-coffee drinkers of similar age, weight, and health background. This imaging and biomarker evidence gives the association a stronger biological foundation than survey data alone could provide.
The scale of the study is also notable. With more than 355,000 participants tracked for an average of thirteen years through the UK Biobank, a large, well-established long-term health research resource, the researchers had enough statistical power to examine relatively rare outcomes like liver cancer and cirrhosis-related death with meaningful precision, and to adjust for a wide range of other factors that might otherwise confound the results, including alcohol consumption, body weight, smoking status, and pre-existing metabolic conditions.
Background: Coffee's Long and Complicated Relationship With Liver Health
Coffee has been the subject of health research for decades, with findings that have sometimes seemed contradictory to casual observers. Early twentieth-century medical opinion occasionally treated coffee with suspicion, associating heavy consumption with cardiovascular risk and digestive complaints. Over the past twenty years, however, a growing body of epidemiological research has consistently pointed toward coffee having a protective association with several liver-related conditions specifically, including non-alcoholic fatty liver disease, a condition affecting a substantial share of adults worldwide that is closely tied to obesity, insulin resistance, and metabolic syndrome.
Prior meta-analyses and systematic reviews had already suggested that regular coffee consumption correlates with reduced risk of fatty liver disease, and some smaller studies had found associations with reduced fibrosis progression in patients who already had chronic liver conditions such as hepatitis. What the new Cedars-Sinai-led research adds is a far larger sample size, a longer follow-up period, and direct biological evidence through imaging and blood proteomics, moving the field from a purely statistical association toward a more mechanistically grounded understanding of how coffee might actually be protecting liver tissue over time.
Coffee's relationship with liver health has also drawn comparisons to other well-established preventive interventions in medicine, such as low-dose aspirin's association with reduced colorectal cancer risk in certain populations, or statins' role in reducing cardiovascular events beyond their primary cholesterol-lowering function. In each of these cases, an intervention originally used or consumed for one purpose was later found, through years of accumulating epidemiological and mechanistic research, to carry meaningful protective effects against a different disease process entirely, a pattern that researchers studying coffee's liver benefits believe may be unfolding in a similar way here.
Key Details: The Possible Biological Mechanisms
Coffee is a complex beverage containing hundreds of bioactive compounds beyond caffeine, including chlorogenic acids, diterpenes, and various polyphenols, several of which have demonstrated antioxidant and anti-inflammatory properties in laboratory research. Researchers studying coffee's effect on the liver have proposed several possible mechanisms, including coffee's capacity to reduce oxidative stress within liver cells, its potential to influence the gut microbiome in ways that reduce inflammatory signaling reaching the liver via the gut-liver axis, and its associations with improved insulin sensitivity, which could indirectly reduce the fat accumulation that drives non-alcoholic fatty liver disease toward more severe stages.
The blood protein, or proteomic, analysis included in the new study allowed researchers to identify specific circulating protein patterns associated with coffee consumption that also correlate with healthier liver function, offering a potential biological pathway connecting the beverage to the clinical outcomes observed. While the exact combination of compounds responsible, and their precise mechanism of action, remains an active area of investigation, the consistency of the association across imaging, blood markers, and hard clinical outcomes such as cirrhosis and cancer diagnosis strengthens confidence that the relationship is not merely coincidental.
Some researchers have also pointed to caffeine's specific effects on liver fibrosis pathways, noting laboratory research suggesting caffeine may inhibit the activity of hepatic stellate cells, the cell type primarily responsible for producing the scar tissue that characterizes fibrosis and, in advanced stages, cirrhosis. If confirmed through further mechanistic research, this would provide a plausible direct biological explanation for why coffee drinkers in the current study showed measurably less fibrotic scarring on liver imaging compared with non-drinkers, beyond the broader antioxidant and anti-inflammatory effects already documented.
It's worth noting that the study examined coffee consumption broadly rather than isolating specific preparation methods, meaning the results likely reflect outcomes across drip coffee, espresso-based drinks, and other common preparations, though some earlier research has suggested that unfiltered coffee preparations may carry different cardiovascular risk profiles due to higher levels of certain oils, a nuance not fully resolved by this particular study.
Why This Matters: Liver Disease Is a Growing Global Health Burden
Liver disease has become an increasingly significant public health concern worldwide, driven substantially by rising rates of obesity and metabolic syndrome, which contribute to non-alcoholic fatty liver disease, now often referred to in updated clinical terminology as metabolic dysfunction-associated steatotic liver disease. Left unaddressed, this condition can progress over years or decades to more severe liver scarring, cirrhosis, and in some cases liver cancer, a progression that is often silent and symptom-free until it reaches an advanced, harder-to-treat stage.
Liver cancer in particular carries a notably poor prognosis compared with many other cancers, in part because it is frequently diagnosed at a later stage, making prevention-focused findings like this one especially valuable from a public health standpoint. A dietary or lifestyle factor that is inexpensive, widely accessible, and already deeply embedded in daily habits for a large share of the global population represents an unusually practical opportunity for meaningful disease prevention, assuming further research continues to support a genuinely protective, rather than merely correlational, relationship.
For clinicians treating patients at elevated risk of liver disease, including those with obesity, type 2 diabetes, or existing fatty liver findings on routine imaging, this research adds to a growing rationale for discussing coffee consumption as one component of a broader liver health conversation, alongside more established recommendations around weight management, alcohol moderation, and physical activity.
Globally, chronic liver disease and cirrhosis are estimated to contribute to well over a million deaths annually, with metabolic dysfunction-associated steatotic liver disease alone now believed to affect roughly a quarter to a third of adults worldwide, a prevalence that has climbed steadily alongside rising global rates of obesity and type 2 diabetes over the past several decades. Liver cancer, meanwhile, ranks among the more rapidly increasing cancer types in several countries, partly reflecting this same underlying rise in metabolic liver disease as a growing share of cases, alongside the more traditionally recognized risk factors of chronic viral hepatitis B and C infection and heavy long-term alcohol use.
Reactions: How Researchers and Clinicians Are Interpreting the Findings
Dr. Kim and colleagues have been careful in public comments to frame the findings as an important addition to the evidence base rather than a basis for blanket clinical recommendations to increase coffee intake, particularly for patients with conditions such as anxiety disorders, certain heart arrhythmias, or pregnancy, where high caffeine intake carries its own established risks that need to be weighed independently. Outside hepatologists and gastroenterologists commenting on the research have generally described it as a well-designed, methodologically rigorous addition to a body of evidence that has been building for years, while cautioning, as is standard practice with observational research of this kind, that it demonstrates association rather than definitively proven causation.
Some researchers have called for follow-up studies isolating decaffeinated coffee's effects specifically, since several bioactive compounds in coffee are not related to caffeine content, a distinction that could clarify whether caffeine itself, other coffee compounds, or some combination is responsible for the observed liver benefits. Others have emphasized that randomized controlled trials, which are more difficult and expensive to conduct for a dietary exposure like coffee consumption over many years, would ultimately be needed to establish a stronger causal claim, even though such trials are unlikely to be conducted at the scale and duration necessary given practical and ethical constraints around long-term dietary intervention studies.
Limitations and Open Questions in the Research
As with any large observational study, the Cedars-Sinai-led research has limitations that both its authors and outside reviewers have been careful to acknowledge. The UK Biobank cohort, while very large, is not perfectly representative of the general population; participants have historically tended to be somewhat healthier and more affluent on average than the broader population from which they were drawn, a pattern sometimes referred to as "healthy volunteer bias" that could affect how the findings generalize to more diverse populations, particularly in regions with different average diets, healthcare access, and rates of underlying liver disease risk factors.
The study also cannot fully rule out the possibility of residual confounding, meaning some unmeasured factor that happens to correlate both with higher coffee consumption and with better liver outcomes could be partly responsible for the observed association, even after statistical adjustment for known confounders like alcohol use, body weight, and smoking. This is a standard limitation of observational epidemiology generally, and it is precisely why researchers in the field continue to describe the coffee-liver relationship as a strong and consistent association rather than a proven causal mechanism, despite the added weight of imaging and biomarker evidence in this particular study.
Additionally, because the study examined coffee consumption as reported at specific points in time, it may not fully capture how people's coffee habits changed over the many years of follow-up, a common challenge in long-term cohort research that relies on periodic rather than continuous data collection.
Historical Context: A Long Pattern of Coffee Research Findings
This is far from the first major study to find a health benefit associated with coffee consumption. Previous large cohort studies have linked moderate coffee consumption with reduced risk of type 2 diabetes, certain neurodegenerative conditions including Parkinson's disease, and modestly reduced all-cause mortality in some populations. At the same time, coffee research has historically had to grapple with confounding factors, since people who drink coffee regularly may differ systematically from those who do not in ways that are difficult to fully account for statistically, including socioeconomic status, other dietary patterns, and health-seeking behavior generally.
The liver-specific research adds to this pattern while standing out for its inclusion of objective imaging and biomarker data rather than relying purely on self-reported consumption and subsequent diagnosis codes, a methodological strength that addresses some, though not all, of the traditional limitations associated with large observational nutrition studies. Researchers in the field generally view the accumulation of consistent findings across many independent studies and populations, using different methodologies, as collectively strengthening confidence in a genuine protective relationship, even in the continued absence of a definitive randomized trial.
Common Questions About Coffee and Liver Health
Readers encountering this research often want practical guidance rather than just the statistical findings. How much coffee is actually needed to see a benefit, whether decaffeinated coffee provides similar protection, and whether adding cream, sugar, or other additives changes the relationship are among the most frequently asked follow-up questions. The current study suggests benefits begin appearing even at modest intake levels of one to two cups daily, though the strongest associations were seen at three or more cups; it did not specifically isolate the effects of common additives, meaning readers with concerns about sugar or dairy intake should weigh those separately against any potential liver benefit from the coffee itself.
Broader Implications for Diet, Public Health Guidance, and the Coffee Industry
If further research continues to support these findings, public health guidance around liver disease prevention could eventually begin to more explicitly incorporate coffee consumption alongside existing recommendations focused on weight management, alcohol moderation, and metabolic health. That said, health authorities have historically been cautious about issuing consumption recommendations based on observational nutrition research alone, preferring to wait for a stronger accumulated evidence base or supportive mechanistic and, where feasible, interventional data.
The coffee industry, which has a long history of funding and publicizing research favorable to the beverage's health profile, is likely to highlight these findings prominently in marketing and public communications, a pattern that has occurred with previous positive coffee research. Public health communicators and independent researchers will likely continue to emphasize that this study, like others before it, should be interpreted within a broader context of overall diet and lifestyle rather than as a standalone health intervention, and that coffee consumption should not be viewed as a substitute for addressing more established liver disease risk factors such as excess alcohol consumption, obesity, and viral hepatitis.
Practical Takeaways for Readers Weighing Their Own Coffee Habits
For readers trying to translate this research into practical decisions, several points are worth keeping in mind. First, the protective association was observed across a wide range of intake levels, meaning people do not necessarily need to dramatically increase their coffee consumption to potentially benefit, particularly if they already have other risk factors for liver disease that would benefit more directly from addressing, such as excess body weight, heavy alcohol use, or poorly controlled diabetes. Second, people with medical conditions affected by caffeine, including certain heart rhythm disorders, anxiety conditions, sleep disorders, or pregnancy, should discuss appropriate caffeine intake with their own physician rather than using this study as a basis for increasing consumption independent of that guidance.
Third, the study examined coffee consumption broadly rather than specific popular coffee-based beverages loaded with added sugar, cream, or flavored syrups, meaning the liver benefits observed likely apply most directly to coffee consumed in relatively simple forms, and readers concerned about calorie intake, blood sugar, or cardiovascular health should still weigh the broader nutritional content of elaborate coffee drinks separately from the coffee itself.
What to Watch Next
Future research building on these findings is likely to explore several open questions, including whether decaffeinated coffee confers similar protective effects, what specific bioactive compounds are most responsible for the observed benefits, and whether the protective association holds consistently across diverse populations beyond the predominantly UK-based cohort examined in this study. Watch also for follow-up commentary from major hepatology and gastroenterology professional societies, which may weigh in on whether and how this evidence should inform future clinical guidance or public dietary recommendations. Finally, expect continued interest from the broader nutrition science community in replicating these imaging and biomarker findings in other large biobank-style cohorts around the world, which would further strengthen or potentially qualify the current conclusions.
This article summarizes publicly reported research findings as of July 27, 2026, and will be updated as more information becomes available.
